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ABSTRACT
Mesenchymal stem cells (MSCs) are promising candidates for adult cell therapies in regenerative
medicine. To fully exert their potential, efﬁcient homing and migration toward lesion sites play
an important role. Local transplantation deposits MSC in spatial proximity to the lesion, but
often requires invasive procedures. Systemic administration routes are favored, but require the
targeted extravasation of the circulating MSC at the site of injury. Transplanted MSC can indeed
leave the blood ﬂow and transmigrate through the endothelial barrier, and reach the lesion
site. However, the underlying processes are not completely dissolved yet. Recent in vitro and in
vivo research identiﬁed some key molecules scattered light on the extravasation mechanism.
This review provides a detailed overview over the current knowledge of MSC transendothelial
migration. We use the leukocyte extravasation process as a role model to build a comprehen-
sive concept of MSC egress mechanisms from the blood stream and identiﬁed relevant similari-
ties as well as important differences between the extravasation mechanisms. STEM CELLS
2017;35:1446–1460
SIGNIFICANCE STATEMENT
Our manuscript provides a concise overview on the current knowledge of the mesenchymal
stem cell (MSC) extravasation and homing mechanisms. We highlight relevant similarities and
important differences to leukocyte migration, which are important for research and potential
downstream clinical implementation of MSC-based therapies.
INTRODUCTION
Mesenchymal stem cells (MSCs) are widely used
for experimental therapies of neurodegenera-
tive as well as immune disorders, diseases of
the skeletomuscular system, and even tumors
[1–4]. Moreover, ﬁrst clinical applications are
underway, attempting to capitalize on the cells’
beneﬁcial effects and immunocompatibility [5,
6]. A particularly interesting MSC ability is their
homing capability, allowing the cells to navigate
to sites of injury and inﬂammation [7]. MSCs are
believed to exert migratory behavior resembling
that of leukocytes [8–10] with respect to cyto-
kine responsiveness and the ability for transen-
dothelial migration (TEM, diapedesis). This
distinct homing capability enables application of
minimally invasive systemic delivery strategies
in clinical practice, facilitating a widespread
implementation of novel MSC-based treatment
protocols. One the other hand, systemic MSC
administration might lead to adverse events such
as pulmonary [11] or (cerebral) microembolism
[12] under certain circumstances. While MSC
homing behavior has been well described in
numerous scenarios, clarity about deﬁnite mech-
anisms and regulation of MSC migration is still
lacking [13–15]. Hence, detailed knowledge on
the MSC migration process is needed to avoid
potential adverse events in the clinical transla-
tion of systemic treatment protocols.
This review summarizes current knowledge
on navigation, homing, and TEM mechanisms
of MSCs after systemic administration.
MSC HOMING DEFINITION: WHERE DO WE
STAND AND WHAT DO WE NEED?
Most attempts to deﬁne “MSC homing” resulted
in relatively vague, mechanistically oriented and
descriptive deﬁnitions. Some approaches are
simply equating it with migration, ultimately
resulting in the delivery of cells to the site of
injury [16, 17], and subsequent exertion of local
effects [18]. Importantly, these deﬁnitions lack
clarity about how and where homing starts as
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REGENERATIVE MEDICINE
well as when it is terminated, or its characteristics [15]. The most
comprehensive deﬁnition so far was given by Karp et al. who
called for a more nonmechanistic deﬁnition and determined
MSC homing as the active or passive arrest of a MSC within the
vasculature followed by transmigration across the endothelium
[13].
As therapeutic MSC administration can be conducted either
systemically or site-speciﬁc, it is necessary to extend the MSC
homing deﬁnition to provide a global picture of enrolled pro-
cesses and mechanisms. Homing from local clusters after site-
speciﬁc transplantation follows chemotactic principles whereas
systemic transplantation also involves travel in and egress from
the vascular system. Hence, there is a need to distinguish
between systemic and nonsystemic homing.
Nonsystemic homing (Fig. 1) requires either recruitment
of local MSC or transplantation of exogenous cells close to
the target area. Directed migration follows activation and
polarization of MSC, during which a front pole is formed. The
front pole guides interstitial locomotion by sensing chemo-
kines released from injured or inﬂamed tissue. Migration is
terminated after reaching the target site.
Systemic homing is a multistep process composed of three
distinctive phases: (a) direct administration into or cell recruit-
ment and ingress to the circulation, (b) extravasation at the
lesion vicinity, and (c) interstitial migration toward the target
site (Fig. 1). In the ﬁrst phase, MSCs are recruited to the cir-
culation from endogenous depots such as the bone marrow,
or exogenous MSCs are systemically administered. Of note,
egress of endogenous MSC into the circulatory system is an
active process involving an additional migration step. In the
circulation, MSCs are transferred to the site of injury via the
vascular system, a process which is guided by chemokine
gradients (see below). The subsequent extravasation phase
comprises capture of ﬂowing MSC, rolling along, and adhesion
to the endothelium, followed by TEM to reach the perivascu-
lar space. Arrest at the endothelium as well as TEM are deter-
mined by MSC and endothelial surface proteins. The homing
process is ﬁnally concluded by the trans-tissue and/or -inter-
stitial MSC migration phase to the lesion site [19], which is
also navigated by chemokine gradient.
MSC EXTRAVASATION
It is considered that MSCs should exit the circulation to be
effective in tissue regeneration and repair after systemic deliv-
ery or recruitment from remote sites. Similar to leukocytes, this
initially involves formation of contact between the endothelium
and the circulating MSC, tethering, and endothelial rolling [20].
Pioneering work to reveal mechanisms behind leukocyte
TEM was performed by the Butcher and Springer groups, sug-
gesting a multistep model of leukocyte extravasation [21, 22]
(Fig. 2). The conceptional ideas behind these processes have
signiﬁcantly improved and historical deﬁnitions of rolling and
adhesion were dramatically reshaped with the discovery of
adhesion surface molecules and their respective ligands [23,
24]. The model of “combinatory speciﬁcity” [23] was estab-
lished in the context of selectin-mediated rolling, chemokine-
triggered activation, and integrin-dependent arrest. Conven-
tional knowledge suggests that MSC TEM is initiated similarly
to that of leukocytes and hematopoetic stem cells [23]. Leu-
kocyte homing and arrest can indeed serve as the conceptual
role model for MSCs as both cell populations share many sim-
ilarities. However, striking differences with respect to these
processes have also been described (Table 1).
Figure 1. Systemic and nonsystemic homing. Recruitment of local progenitors or transplanted mesenchymal stem cell (MSC) is based
on a chemokine gradient released from the injured site. Systemic homing is inevitable after intravasal transplantation and requires
active or passive MSC extravasation followed by chemokine guided interstitial migration toward the injury. Occasionally, endogenous
MSCs are recruited to the injured tissue via the vascular system. Local transplantation circumvents the journey through the vascular sys-
tem, so the nonsystemic homing is based on migration through tissue in spatial proximity to the injury. Abbreviation: MSC, mesenchy-
mal stem cell.
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As known from electron microscopy studies, leukocyte
TEM is an active process, requiring structural modiﬁcation of
the transmigrating cell. In contrast, MSCs can also become
passively arrested within capillaries, potentially representing
an alternative to active adhesion. MSCs, being signiﬁcantly
larger than leukocytes, become entrapped in small-diameter
vessels during passive arrest [13, 25]. It is unclear whether or
not passive MSC arrest initiates TEM, and the fate of passively
arrested MSCs is still undetermined. The only difference
between active and passive arrest veriﬁed so far is the alter-
ation of the local blood ﬂow. During active stop, the cell ﬂat-
tens swiftly, preventing local blood ﬂow disturbances. In
contrast to selectin- and integrin-mediated capture, cell ﬂat-
tening is not observed during passive arrest, what can lead to
local blood ﬂow impairments. A particular risk is “nonspeciﬁc”
passive arrest in pulmonary, hepatic, splenic, and cerebral
capillaries, which can cause microembolism [26–29]. Under-
standing of passive arrest mechanisms is therefore essential
for MSC therapy development and, potentially, optimization
with respect to safety and efﬁcacy.
Another remarkable difference between leukocytes and
MSC was found in TEM duration. While leukocytes can com-
plete diapedesis within 20 minutes, MSC diapedesis requires
the three- to sixfold time [30, 31]. Although there seems to
be a difference between duration of the migration itself, a
long MSC presence in the circulation will not lead to an
enhanced migration [30].
Previous studies to reveal the mechanisms of TEM were
mainly based on MSCs from exogenous sources and involved
in vitro cultivation and expansion [31–33]. Endogenous MSCs
reside within the bone marrow or perivascular niche and
migrate toward (lesion) sites after mobilization [34, 35].
Detection and studying of endogenous MSC migration is, how-
ever, challenging and resulted in controversial results, as their
characteristics and immunophenotype might differ from
culture-expanded MSCs [36]. Eggenhofer et al. presented two
potential recruitment routes for endogenous MSCs. The ﬁrst
hypothesis describes the attraction and migration of MSCs
from the bone marrow through the circulation. This process is
guided by cytokines, chemokines, and growth factors such as
Figure 2. Multistep model of leukocyte and mesenchymal stem cell (MSC) extravasation. Pro-inﬂammatory mediators initiate a cascade
of endothelial and leukocyte/MSC adhesion and motility responses. Initially, the ﬂowing cell is captured through the interaction of sur-
face molecules and a low afﬁnity contact to the vascular wall is established. The cell then slows down during rolling until arrest. Firm
attachment and intraluminal crawling are mediated by interaction of adhesion molecules. During crawling, the cell polarizes and scans
the endothelium for exit cues. At the right spot, the cell overcomes the endothelial barrier, the endothelial basement membrane, and
the pericyte sheath before continuing chemokine guided interstitial migration.
Table 1. Comparison of leukocyte and MSC extravasation
Parameter Leukocyte MSC
Intravasation Active Active (1 Passive by transplantation)
Extravasation Active Active1 Passive
Duration About 20 minutes 60–120 minutes
Routes Transcellular, paracellular Transcellular, paracellular, (integration)
Rolling Mandatory Possible, but not required
Firm adhesion Mandatory Mandatory
Crawling Formation of invadosomes, protrusion, ﬁlo-,
and lamellipodia; lateral migration
Formation of pseudo- and ﬁlopodia, membrane
blebbing; no lateral migration
Crossing the endothelial
barrier
Guided by endothelial cells, Rho dependent,
PI3K signaling
MSC-endothelial cooperation, formation of
transmigratory cups
Crossing the basement
membrane
Interplay of several MMPs and TIMPs MMP-2/TIMP-3 interplay, Urokinase-type
plasminogen activator
Abbreviations: MMP, Matrix metalloproteases; MSC, mesenchymal stem cell; PI3K, Phosphoinositide 3-kinase; TIMP, Tissue inhibitor of
metalloproteases.
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stem cell factor or stromal-derived factor 1 (SDF-1), all of
which are released from the injury site. The second hypothe-
sis assumes that local MSCs are recruited from within the
injured tissue and migrate through the stroma or reach their
destination via microcapillaries [36]. In contrast to migration
of exogenous MSCs, however, reports on (transendothelial)
migration mechanism of endogenous MSCs are scarce, not
providing enough information to draw a comprehensive pic-
ture so far. One the other hand, there is no study indicating
fundamental mechanistic differences between migration of
endogenous and exogenous MSC toward a lesion site.
MOLECULAR SIGNALS CONTROLLING MSC EXTRAVASATION
A multitude of molecular signals and messengers including
growth factors and chemokines [37] plays an essential role for
the MSC homing process. Most of these trafﬁcking signals also
control the well-orchestrated sequential process of leukocyte
extravasation. They were ﬁrst identiﬁed to control neutrophil
diapedesis before being later found to navigate lymphocytes
extravasation in general [22]. This inspired the concept of a
ubiquitous cell migration control system. In fact, MSC extravasa-
tion is governed by the same surface receptors and migratory
cues, although MSC extravasation displays some important dif-
ferences to leukocyte egress as shown above (Table 1). The most
important molecules and events for leukocyte and MSC homing
and extravasation are given in Table 2.
PRIMING AND REQUIREMENTS FOR EXTRAVASATION
Endothelial cells contribute to extravasation by eliciting crucial
signal responses upon contact with the extravasating cell [69].
This requires endothelial activation being characterized by an
upregulation of receptors on the endothelium in response to
mediators released by inﬂamed tissue. Those mediators are
soluble factors such as tumor necrosis factor alpha (TNFa) or
histamine, with the latter inducing activation of P-selectin on
the endoluminal surface within a few minutes [49]. E-selectin
expression is increased by TNFa and interleukin (IL)-1b and
peaks after 3–4 hours [49]. Inﬂammatory mediators also
stimulate vascular cell adhesion molecule 1 (VCAM-1) and
Intercellular adhesion molcule 1 (ICAM-1) expression [31, 70].
The upregulation “primes” the endothelium for transmigration
by activation of intracellular signaling pathways.
On the side of the extravasating cells, the expression of
ligands is relevant for TEM and includes the upregulation of CD44
(HCAM) and CD49d (Very late antigen 4; VLA-4) [26]. Adhesion
receptors permit the circulating cell to scan “the endothelium.”
After the matching, endothelial “signal expression pattern” was
found [71], and receptor activation leads to ﬁrm adhesion.
Breakdown of the basal membranes and extracellular
matrices as well as local chemokines favor locomotion and tis-
sue reconstitution. The migrating cell literally “blazes” its trail
through the surrounding tissue by using proteases being pro-
duced after cytokine or chemokine stimulation.
Taken together, a set of preconditions including expression,
upregulation, and activation of adhesion molecules have to be
fulﬁlled for extravasation of circulating cells. All relevant
processes are described in more detail in the following
paragraphs.
Cell Capture and Rolling
Selectin-Mediated Rolling. Selectins are evolutionary highly
preserved cell surface receptors, which are expressed in the
vascular system. They are composed of a single transmem-
brane chain and a unique N-terminal extracellular domain.
The N-terminus contains a Ca21-dependent lectin domain, an
epidermal growth factor (EGF)-like domain, and short consen-
sus repeat units, which control ligand speciﬁcity, receptor sta-
bilization and oligomerization [72]. Interaction of P-, L-, and
E-selectins with P-selectin glyocoprotein ligand 1 (PSGL-1)
mediates tethering and rolling of leukocytes (Fig. 3). Although
PSGL-1 is expressed on all leukocytes, it is only functional
when it is glycosylated correctly [23, 73]. The establishment
of low-afﬁnity contacts followed by perpetual formation and
breakup of bonds between leukocytes and endothelium con-
tributes to the reduction in the velocity of passing leukocytes
[74]. Formation of selectin bonds is dependent from shear
stress, what can be related to a “catch-bond” phenomenon of
selectins [75]. Furthermore, it is known that selectin-mediated
leukocyte rolling and deceleration is supported by formation
of slings (5 cell autonomous adhesive substrates) [76, 77]
and microvilli ﬂattening [47].
Contrasting leukocytes, selectin receptor expression is not
observed on MSCs [26, 78]. While the coordinated rolling
behavior of leukocytes is a prerequisite for adhesion, MSCs
tethering and rolling cannot rely on selectin ligands. Selectin-
mediated rolling may not be decisive for establishing ﬁrm
adhesion as long as MSCs are slowed down or become pas-
sively arrested by other means, potentially including passive
arrest. Most interestingly, MSC rolling depends on P-Selectin
expression on activated endothelium in vitro and in vivo [9].
Although neither P-selectin glycoprotein ligand 1 (PSGL-1) nor
CD24 expression was found on MSCs; blocking experiments
revealed that P-selectin controls rolling. This strongly suggests
the existence and relevance of other ligands (Fig. 3). Indeed,
MSCs have been shown to express glycoproteins [79] and
galectin-1 [80], which may represent alternative P-selectin
ligands. Furthermore, interaction of MSCs with P-selectin
might be mediated by a bridging mechanism involving plate-
lets. A recent study showed that platelet depletion in a
murine model of dermal inﬂammation decreased MSC trafﬁck-
ing [27]. Spatial proximity or direct contact of MSCs to plate-
lets or neutrophil-platelet clusters may arbitrate adhesion to
endothelium. Dependence of MSC rolling from shear stress
was also demonstrated, suggesting a catch-bond mechanism.
Integrin-Mediated Rolling. Integrins are heterodimeric trans-
membrane receptors consisting of an a- and b-subunit. They
participate in leukocyte rolling and mediate ﬁrm adhesion. In
addition, integrin heterodimers are able to induce selectin-
independent rolling and strengthen cell binding to the endolu-
minal layer [81]. Three different conformations result in low,
intermediate, or high activity of integrins. This is crucial for
ligand binding and afﬁnity [82, 83]. Next, a distinct change in
the integrin distribution on the cell (valency) induces cytoskel-
eton adaptation and formation of signalosomes [23, 84], and
in turn inﬂuencing binding strength of captured cells to the
endothelium. Finally, the interplay between VLA-4 (a4b1) and
VCAM-1 as well as the interaction of Lymphocyte function-
associated antigen 1 (LFA-1) or Lymphocyte Peyer patch
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adhesion molecule (LPAM) (a4b7) with MadCam-1, VCAM-1,
or ICAM-1 induces rolling behavior of leukocytes [23]. b2-
Integrins are crucial, as they reduce leukocyte velocity follow-
ing selectin-mediated capture [23, 84]. Binding of L- or E-
selectin triggers the initial change in integrin afﬁnity from low
to intermediate state and allows transient binding of ICAM-1.
MSCs express a broad spectrum of integrins including b1,
b2, a1, a2, a3, a4, a5, a6, and aV [85, 86]. Particularly,
expression of a4 subunit varies under different isolation and
cultivation techniques as well as between individual donors
and, importantly, species. This resulted in different observa-
tions regarding MSC adhesion behavior [9, 30, 85]. Noncova-
lent assembling of a4 and b1 is necessary to form VLA-4, an
important mediator of endothelial rolling and arresting at
sites of inﬂammation. A few studies pointed out the impor-
tance of VLA-4 for MSC adhesion on inﬂamed endothelium,
but it remains open what role naturally expressed integrins
play in MSC rolling. Nevertheless, induced ectopic overexpres-
sion of the a4 subunit has been found to enhance bone hom-
ing and engraftment of transplanted MSCs in mice [87]. As
the b1 subunit is abundantly expressed by MSCs, the subse-
quent assembling of both subunits resulted in increased
expression of functional VLA-4 on the cells [87]. Interaction of
b1 subunit with VCAM-1 and extracellular matrix (ECM) com-
ponents is of particular importance for rolling and ﬁrm adhe-
sion of MSC. Hence, blocking of b1 substantially decreases
homing capabilities [88].
Cell Activation and Firm Adhesion to the Endothelium
Chemokine receptor interaction enables chemo- or haptotaxis
of mobile cells. Once bound to their ligand, chemoattractant
receptors direct migration, promote integrin adhesiveness, and
stimulate degranulation as well as rearrangement of the cyto-
skeleton [22]. After initial endothelial activation, chemokines
can be locally expressed at the vascular endothelial surface or in
the ECM where they are bound to glycosaminoglycanes [89].
During slow rolling, the leukocyte is exposed to immobilized
chemokines at the apical (endoluminal) site of endothelial cells
[20]. Binding of the chemokines to leukocytic G protein-coupled
receptors (GPCRs) induces downstream signaling, resulting in
straightening of inactive integrin receptors and exposure of a
binding pocket [82] (Fig. 3). Monocyte GPCRs can cause Phos-
pholipase C (PLC) activation, resulting in an increase in intracel-
lular Ca21-levels and triggering an enhancement of integrin
afﬁnity. Ca21-ions activate guanine-exchange factors which in
turn activate small GTPases such as Rap1 or Rho a [23]. One of
the targets from this downstream signaling is talin, an intracellu-
lar adapter protein that moves to the cell membrane and inter-
acts with the b-subunit of the integrin receptor [81]. Distance
widening between cytoplasmic tails of both subunits leads to
straightened position of the integrin receptor, and thus, expo-
sure of a binding pocket. The resulting afﬁnity increase as well
as further integrin recruitment is particularly important for
establishing strong and shear-resistant leukocyte adhesion to
the endothelial cells [23, 47, 90]. In addition, actin polymeriza-
tion is enhanced after leukocyte activation, and thus, promotes
formation of lamellopodia necessary for probing the endolumi-
nal surface [91].
Active, surface molecule-mediated MSCs adhesion to the
endothelium is discussed as a core mechanism of the homing
process [13]. Expression of numerous chemokine receptors
including C-C chemokine receptors (CCR)2, CCR4, CCR7,
CCR10, CXCR5, CXCR6, and CXCR4 was already shown for
MSCs [89, 92, 93]. It is still unclear how these chemokine
receptors contribute to extravasation. Although expressed,
CXCR4 for instance does not contribute to TEM in MSCs [86].
In contrast, other researchers presented evidence that CXCR4
plays a major role for MSC homing [39, 93–96]. It is not
unlikely that those conﬂicting results simply derive from dif-
ferent handling, isolation, and cultivation conditions. In vitro
assays and screenings have identiﬁed the cytokine receptor
CCR2 as being necessary for organ-speciﬁc homing [97, 98].
It was reported that enforced hematopoietic cell E- and L-
selectin ligand (HCELL) expression on human MSCs leads to
robust osteotropism [99]. Expression of HCELL induces binding
to endothelial E-selectin. Interaction of HCELL with selectin
also affects adhesion of MSC to VCAM-1 and triggers activa-
tion of G-protein signaling while bypassing chemokine recep-
tor signaling [100]. Blocking experiments showed that ﬁrm
adhesion is established by VLA-4/VCAM-1 interaction which in
turn is mediated by Rac1/Rap1 GTPase signaling [99]. So far,
the full range of downstream mediators involved in signaling
for MSC TEM has not been elucidated, with only a few signal-
ing pathways being identiﬁed so far (Fig. 3). Phosphokinase C
(PKC), for example, is upregulated in an IL-8 dependent man-
ner in human MSCs [101] and Phosphoinositide 3-kinase
(PI3K)/Act plays a corresponding role [30]. As integrins lack
enzymatic activity, an intracellular adapter is required to
transduce signals from outside or from the inside [102]. One
of those adapters is the integrin-linked kinase (ILK). It is con-
ceivable that ILK also plays a role for MSC TEM and signaling.
Song et al. have shown that overexpression of ILK in MSC
leads to their increased adhesion to the infarcted myocardium
and to improved cell survival after hypoxia [103].
Endothelial Scanning, Crawling, and Cell Polarization
Leukocytes search for exit cues after establishing a ﬁrm endo-
thelial adhesion [91]. To this end, the leukocyte “scans” the
endothelium along chemotactic gradients and moves along
the inner vessel walls (5crawling). Endothelial crawling
requires integration of inside-out integrin activation upon che-
mokine binding, outside-in integrin signaling, and chemokine
receptor-induced cytoskeletal remodeling [104].
Lateral movement is accompanied by formation of protru-
sions, lamellipodia, ﬁlopodia, and invadosomes for motility and
pathﬁnding and is observed as soon as leukocytes are starting
to polarize [31, 32] (Fig. 4). Signaling via src family kinases and
activation of syk are crucial for cellular polarization and cell
shape changes [105]. Chemokine-GPCR downstream signaling
triggers reorganization of the leukocyte actin cytoskeleton, gen-
erating a protrusive front pole and a contractile uropod. Fur-
thermore, Rho/ROCK signaling is linked to formation of
protrusions and lamellipodia [65] in response to chemokine sig-
nals [24]. Crawling behavior was observed with or against the
blood stream as well as perpendicular to it [47]. It is assumed
that crawling allows the leukocyte to sense the best location for
TEM but is not essential to the process itself because inhibition
of crawling only prolongs, but not prevents TEM [106].
MSCs also require polarization before TEM. The intracellu-
lar adapter molecule FROUNT, linked to CCR2, is necessary to
polarize MSCs, which is followed by CCR2 clustering and leads
to cytoskeletal reorganization [97]. MSCs show little lateral
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Figure 3. Rolling, cell activation, and ﬁrm adhesion of leukocytes and mesenchymal stem cell (MSC). Rolling along the inner vascular wall is
mediated by selectins and integrins. Transitory bonds are established and dissolved between selectin receptors and their respective ligands.
Tethering activates the integrin receptors. E-selectin and LFA1 play an important role in leukocyte rolling. MSC rolling is obligatory and is facil-
itated by galectin1 or platelet bridging that act as alternatives for selectin-mediated adhesion. Cell activation and ﬁrm adhesion to activated
endothelium: A chemokine binds to its cognate G protein-coupled receptor. Small GTPases get activated and target the cytoplasmic domain
of the VLA-4 receptor via the adaptor protein talin. This interaction causes an allosteric switch exposing the extracellular binding site. The
erected form of the integrin receptor further facilitates receptor clustering, lateral movement, and triggers migration, adhesion, or diapede-
sis. While the contributing molecules and signaling pathways are relatively well investigated, their role in MSC activation is primarily derived
from the leukocyte model. Abbreviations: ESL-1, E-selectin ligand 1; GEF, guanine-exchange factor; GPCR, G protein-coupled receptor; HCELL,
hematopoietic cell E- and L-selectin ligand; IL-8, interleukin-8; PLC, Phospholipase C; PSGL-1, P-selectin glycoprotein ligand 1; s-LEx, sialyl
Lewis x; VCAM, Vascular cell adhesion molecule 1; VLA-4, Very late antigen 4.
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migration on the endothelium during polarization, which is in
contrast to leukocytes (Fig. 4). However, MSCs are able to
form ﬁlopodia after stimulation with CXCL-9 and crawl on
endothelial cells. This is followed by formation of pseudopodia
and spreading in vitro [26]. In distinction from leukocytes
TEM, MSC TEM does not involve invadosomes or lamellipodia.
Instead, MSCs share a number of interesting characteristics
with the extravasation of germ cells or metastatic tumor cells
including non-apoptotic blebbing [31, 107]. MSCs are sup-
posed to form bleb-like protusions (cup-like structures) on the
cell surface, particularly at sites of close contact with the
endothelium [31].
Crossing the Endothelial Barrier
Overcoming the Endothelial Monolayer. Any transmigrating
cell has to overcome three barriers: endothelial cells, the base-
ment membrane, and the pericyte sheat [23]. The guidance of
the leukocyte through endothelial junction (or pores) requires a
strict coordination of the interaction between endothelial
monolayer and the transmigrating leukocyte [47]. When the
leukocyte has found an optimal spot for TEM, integrin binding
to ICAM-1 or VCAM-1 activates signaling pathways that lead to
high receptor trafﬁcking in the endothelial cell (Fig. 5). Further-
more, ICAM-1 and VCAM-1 clustering facilitates the formation
of transmigratory cups, which are ﬁnger-like protrusion sur-
rounding the adherent leukocyte and providing directional guid-
ance [90, 91]. The inter-endothelial cell–cell connections
formed by adherens (Vascular endothelial cadherin, VE-cad-
herin), gap (connexins), and tight junctions (occludin, claudin,
and junctional adhesion molecules) are disassembled upon acti-
vation and clustering of ICAM-1 or VCAM-1. This eases the leu-
kocyte passage [24, 91]. Importantly, endothelial connections
are subsequently recycled in the so-called lateral border recy-
cling compartment providing new membranous components
surrounding the passing leukocyte. The leukocyte itself has to
relocate integrin adhesion molecules when passing the endo-
thelium, what comprises inactivation of GTPases, antagonizing
Rho/Rap activities, as well as regulation by PI3K signaling and
PKC [47]. In particular, PI3K signaling is associated with disrup-
tion of endothelial tight junctions [108].
Also MSCs and endothelium actively cooperate to enable
guidance by transmigratory cups, a form of endothelial protru-
sions [31]. It can be assumed that MSC-endothelial cooperation
may induce similar endothelial signaling and reorganization as
seen after leukocyte adhesion. However, in vitro life cell imag-
ing studies on transmigrating MSCs suggested an important
role of blebs that might mediate intercellular forces against
endothelium [31, 109] (Fig. 5). Moreover, bone marrow-derived
MSC TEM was shown to depend from PI3K and ROCK in knock
down experiments [110]. In accordance to leukocytes, Rho was
identiﬁed as a regulator of cytoskeletal activation and a modu-
lator of MSC transmigration. Rho inhibition led to resolution of
actin stress ﬁbers and increased the amount of cytoplasmatic
protrusions. Rho inhibition also enhanced chemotactic migra-
tion toward PDGF, HG, LPA, and S1P [111].
Overcoming the Basement Barrier and the Pericyte
Sheat. Finally, migrating leukocytes enter the subendothelial
space via a lamellopodial leading edge (Fig. 5). This movement is
guided by platelet endothelial cell adhesion molecule (PECAM-
1, CD31), CD99, and junctional adhesions. The endothelial basal
membrane consists of laminins and collagen type IV. Proteolytic
cleavage by matrix-metalloproteinases or elastases facilitates
leukocytic passing of this barrier. Beside degradation mecha-
nisms, existence of leukocyte-permissive regions is discussed
aligning with gaps between adjacent pericytes. Those gates
show low matrix protein deposition and are enlarging in
response to different inﬂammatory stimuli [112]. The leukocyte
Figure 4. Leukocyte crawling versus mesenchymal stem cell (MSC) crawling. During crawling onto the endothelial layer, the leukocyte
moves into various directions to ﬁnd the optimal spot for transendothelial migration. The leukocyte polarizes and forms cytoplasmic
extensions (ﬁlopodes and lamellipodes). Additional leukocytic membrane protrusions (invadosomes) are advancing into the endothelial
cell body and are mediated by ICAM-1. MSC crawling does not occur in an extensive manner and lateral movement is reduced. The
MSC advances against the endothelial barrier by the formation of blebs.
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is then attracted by pericytes expressing ICAM-1 and is further
guided by pericyte-borne chemoattractants [113].
Urokinase-type plasminogen activator (PA) has been found
in MSC protrusions (Fig. 5) and can support migration of MSCs
under ERK 1,2 MAPK signaling [114]. Overcoming the endotheli-
al basement barrier by MSCs involves proteases including colla-
genases and metalloproteinases such as Matrix metalloprotease
2 (MMP-2). MMPs are able to degrade the basal membrane col-
lagen type IV, and Tissue inhibitor of metalloprotease 3 (TIMP-
3). MMP-9 seems to play a minor role [10, 32, 52], while knock
down of MMP-2 severely impairs the migration of MSC over
endothelial basement membrane [10].
Different Ways Trough the Endothelial Barrier
Two main routes for leukocyte TEM have been described [74,
115]. Paracellular migration between neighboring endothelial
cells is used to pass endothelial cell junctions and accounts
for the majority of extravasating leukocytes [23]. Besides that,
a transcellular route directly through an individual endothelial
cell was observed for 5%–20% of leukocytes and occurs espe-
cially after contact to ICAM-1 [90, 91].
Paracellular migration is also the main route observed for
MSC TEM. Importantly, it does not induce morphological
changes to the endothelial barrier. However, it decreases
transendothelial electrical resistance and alters localization of
endothelial tight junctions [116]. Formation of a gap between
endothelial cells by dissolving of inter-endothelial cell contacts
allows MSC to overcome the endothelial barrier [30, 110,
116]. Another mechanism called active vascular expulsion
depends on endothelial pocketing. This extravasation process
requires activity from endothelial cells to guide migrating cells
though the endothelial barrier [117]. Integrins are required
for pocketing while vascular breakdown necessitates MMPs.
Of note, endothelial pocketing is so far described only for
MSC forming multicellular spheres or cardiospheres after culti-
vation on ultralow attachment culture dishes [117] .
Transcellular diapedesis occurs by the formation of an
intracellular window for cell passage in a tunnel-like manner,
and was recently described for leukocytes [115]. It is unclear
though whether this also plays a major role for MSC TEM as
only a single publication [31] reported a route directly
through the endothelial cell so far.
Figure 5. Leukocyte and mesenchymal stem cell (MSC) crossing of endothelial barrier. Transendothelial migration (TEM) involves coordi-
nated assembly and disassembly of adhesion molecules (VE-cadherin, integrins, connexins, and tight junctions). Endothelial adhesion
molecules are temporarily occupied by the transmigrating cell addressing complex signaling pathways. Receptor internalization and recy-
cling within the lateral border recycling compartment are mediated by phosphorylation and dephosphorylation, and can further involve
proteolytic cleavage and alteration of cytoskeletal anchorage. Cytoskeletal remodeling facilitates opening of endothelial junctions and
eases the passage of the transmigrating cell. As soon as the leading edge reaches the basal lamina, proteolytic enzymes are released for
basal lamina breakthrough. An ICAM-1 interplay regulates the passage through the pericyte sheath. Of note, molecular signaling during
TEM of MSC is not completely elucidated yet, leaving several ambiguities. Abbreviations: ICAM, Intercellular adhesion molecule 1; JAM,
junctional adhesion molecule; LBRC, lateral border recycling compartment; LFA-1, Lymphocyte function-associated antigen 1; MMP,
Matrix metalloprotease; PA, Plasminogen activator; PECAM, Platelet endothelial cell adhesion molecule 1; VCAM, Vascular cell adhesion
molecule 1; VLA-4, Very late antigen 4; VE, Vacular endothelial cadherin.
Nitzsche, M€uller, Lukomska et al. 1455
www.StemCells.com VC 2017 The Authors STEM CELLS published by
Wiley Periodicals, Inc. on behalf of AlphaMed Press
Furthermore, an integration process, deﬁned by endotheli-
al retraction as well as MSCs spreading and integration was
described [30, 32, 118]. That mechanism is usually not consid-
ered a TEM process, but may involve similar induction mecha-
nisms as “true” TEM.
STRATEGIES TO ENHANCE MSC HOMING, MIGRATION, AND
TRAFFICKING
Recent advances in molecular biology have augmented the
opportunities for adjustment and manipulation of stem cell
functionality and are mainly exerted by means of genetic
engineering [119]. Genetic engineering of MSCs can be real-
ized by numerous methods including the use of integrating
and non-integrating viral vectors as well as delivery of
plasmid-DNA or mRNA [119]. The element of modiﬁcation is
of similar importance. Mobility and homing via the SDF-1 axis
is enhanced by transfection of CXCR4 [39, 94]. Integrating vec-
tors have been used to insert chemokine receptors to MSCs
using lentiviral vectors to transfer CXCR4 to rat MSC [120].
Although lentiviral modiﬁcations rise safety concerns due to
the nonspeciﬁc integration sites, the efﬁciency particularly in
resting or slowly proliferating cells is high [119]. Furthermore,
it has been described that lentiviral transfection does not rel-
evantly affect the differentiation potential [121]. Moreover,
ectopic expression of alpha4/beta1 integrin in MSCs mediated
by adenoviral transfection enhances homing to the bone in
mice [87]. Adenoviruses are suitable to infect a broad variety
of stem cells while having a low immunogenicity. Modiﬁcation
with integrating viral vectors generates long-term expression
of the transgene, what makes them a practical tool for proof
of principle research, but not for clinical use.
Another approach is transgene delivery via plasmids.
Translocation of plasmid DNA to the nucleus is required to
produce mRNA for protein translation, but the DNA does not
integrate into the host genome and is only transiently trans-
lated, increasing the methods safety. This is believed to facili-
tate clinical use, but currently comes at the cost of low
efﬁcacy. To address this problem, a broad variety of transfec-
tion kits is available, but need to be optimized for MSCs. For
instance, Marquez-Curtis et al. achieved a maximum transfec-
tion efﬁciency of 40% for cord blood derived MSCs using IBA-
fect while maintaining differentiation capabilities but affecting
proliferation rate [39] .
Transient overexpression of relevant cell surface receptors
can be also achieved by mRNA. For example, human MSCs
were transfected with mRNA carrying the CXCR4 gene for
CXCR4 tagged with green ﬂuorescent protein [122]. The great-
est advantage of mRNA transfection is the bypass of the
nucleus since cytoplasmic mRNA is directly accessible for
translation [119]. Electroporation [122] and cationic lipids
[123] have been shown to improve mRNA transfection efﬁca-
cy. Transfection is transient due to cytoplasmic instability of
mRNA [124], allowing the transfected cell to home within a
certain time window.
Besides the cell surface modiﬁcation by genetically
induced receptor expression, enzymatic manipulation of
endogenously expressed surface proteins can be used [125].
An example for enzymatic conversion was given by Kerkela
et al., who showed that cleavage of cell surface structures can
increase MSC targeting and decreases pulmonary entrapment
[126]. In particular, use of pronase instead of trypsin for
detachment of cultured MSC resulted in faster lung clearance
due to cleavage of ﬁbronectin-binding receptors. Instead of
cleavage, enzymatic modiﬁcations can be used to create mole-
cules on the cells’ surfaces. Generation of HCELL as an E-
selectin ligand is achieved by glycosyltransferase (d)-pro-
grammed stereosubstitution, converting naturally expressed
CD44 into its sialofucosylated glycoform [127].
Direct MSC capturing from blood ﬂow by interaction of
endothelial adhesion molecules with selective ligands is of
limited effectiveness [128]. It can be improved though by
noncovalent coupling of a PSGL-1-IgG1 fusion construct to the
MSC surface using palmitated protein G (PPG) [129]. PPG-
based modiﬁcation is also suitable to bind antibodies against
adhesion receptors on the inﬂamed endothelium as shown
for ICAM-1 [130]. Tethering and rolling to P- and E-selectin
carrying endothelial cells can further be enhanced by MSC
surface modiﬁcation using conjugation of sialyl Lewis X (sLeX)
moiety via Biotin–Streptavidin under optimized conditions [5].
Hydrophobic tails can serve as an anchor for ligands with lipid
or alkyl chains [131], but have been shown to offer little resis-
tance to mechanical forces occurring during rolling and adhe-
sion. Firm adhesion under shear stress can be achieved by
coupling peptides to membrane proteins with N-hydroxy-suc-
cinimide polyethylen glycol 2 (NHS-PEG2). This construct
serves as a linker and does not affect cell viability as well as
proliferation and differentiation potentials [132].
Improving endothelial adhesion properties is a valid strat-
egy to improve MSC homing, but migration can also be
addressed through the manipulation of other regulators. For
instance, the phosphoprotein focal adhesion kinase (FAK)
serves as a central downstream cytoskeletal regulator of sev-
eral receptors and proteins such as aquaporin 1 (AQP-1) [55],
platelet-derived growth factor receptor [133], or EGF [134].
Enhanced migration of MSCs was shown after AQP-1 overex-
pression in a femoral fracture model. Accordingly, FAK and b-
catenin were upregulated [55, 135]. Transcription factors, such
as T-cell factor/Lymphoid enhancer-binding factor (TCF/LEF)
[136] or Sox11 [137] control central stem cell characteristics
including migratory behavior. Sox11 upregulation activates
BMP/smad signaling pathway and initiates MSC migration
[137]. Nuclear receptor nurr77 and nurr11 genes are enrolled
in the migration of active cell populations [138]. Migration
depends on quantitative relationships among the constituents
of several pathways [134], and can therefore be affected and
potentially controlled by factor regulation on various levels of
the respective intracellular signaling cascades.
The aforementioned methods for enhanced homing are
based on artiﬁcial modiﬁcations and thus generally harbor the
risk of undesired side effects. Culture conditions, cell source,
and manipulation can induce endogenous expression of sur-
face and adhesion receptors [139, 140]. Expression proﬁles for
surface receptors and thereby homing capabilities change
considerably with culturing over several passages, and are fur-
ther inﬂuenced by medium composition and oxygen concen-
tration [141] or pretreatment [142]. For example, protein C
kinase inhibitor Ro-31-8425 increases adhesion to ICAM bind-
ing domains of MSCs in vitro and in vivo [143]. Furthermore,
cytokine pretreatment/preconditioning can augment MSC
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adhesion and homing to ischemic tissue as shown for TNFa
[144] and IGF-1 [145].
In living organisms, MSCs are physiologically situated in
hypoxic environments with an oxygen concentration between
2% and 9% [61]. Therefore, maintenance of low oxygen during
MSC cultivation supports their physiological characteristics
[139], including surface receptor expression and stemness
[146]. Hypoxic preconditioning also induces the expression of
prosurvival genes, decreases ischemic cell death and increases
trophic activity [147] particularly favorable properties for ther-
apeutic transplantation.
Another approach involves the application of stimulating
agents or pharmaceuticals to increase proliferation and mobi-
lization of endogenous MSCs from the bone marrow upon
injury. G-CSF and VEGF were considered to have a stimulating
effect on MSCs, increasing the number of circulating MSCs in
the peripheral blood [13, 148, 149]. It is, however, unclear
whether mobilized MSCs also home more efﬁciently toward
injury, or if just their number increases.
CLINICAL RELEVANCE OF (IMPROVED) SYSTEMIC MSC
TRANSPLANTATION
The beneﬁts of using MSCs for regenerative medicine are
numerous and have been proven in many studies [1, 2, 150]. A
particular advantage of MSCs compared with the application of
certain pharmaceuticals is their capability to secrete a cocktail of
bioactive factors in response to their environment [151]. This
ﬂexibility circumvents several difﬁculties as seen, for example,
with drug dosing [151] or monodrug treatments. However, the
therapeutic impact of this ﬂexibility relies on the presence of
MSCs in close spatial proximity to the injury. The invasive
character of local transplantation might be not feasible for wide-
spread clinical application. This particularly applies to sites of
injury that are hard to reach or to organs such as the heart and
the brain, to which a local injection would provide a consider-
able risk. In this context, a successful systemic transplantation
including efﬁcient homing toward injury sites is of signiﬁcant rel-
evance. Long-term treatment without a stressful intervention
further allows repeated transplantation through a remote artery
and vein and would, thus, ease the application. Furthermore,
conditions have identiﬁed that even allow systemic MSC trans-
plantation with high viability and maintenance of a deﬁned
secretome [152]. Understanding the process of TEM and factors
contributing to it may provide the tools for enhancing MSC hom-
ing after systemic transplantation.
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